Nukacin ISK-1, a bacteriostatic lantibiotic

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3595-3598

  Asaduzzaman, Sikder M ^a   Nagao, Jun Ichi ^b   Iida, Hiroshi ^a   Zendo, Takeshi ^a   Nakayama, Jiro ^a   Sonomoto, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA DENTAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ISK 1; NISIN A; NUKACIN; POLYPEPTIDE ANTIBIOTIC AGENT; POTASSIUM ION; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACILLUS SUBTILIS; BACTERIOCINS; MEMBRANE POTENTIALS; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; NISIN;

EID: 67749108277     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01623-08     Document Type: Article

References (14)

1. Asaduzzaman, S. M., J. Nagao, Y. Aso, J. Nakayama, and K. Sonomoto. 2006. Lysine-oriented charges trigger the membrane binding and activity of nukacin ISK-1. Appl. Environ. Microbiol. 72:6012-6017.
2. Aso, Y., K. Okuda, J. Nagao, Y. Kamenasa, N. T. B. Phuong, H. Koga, K. Shioya, T. Sashihara, J. Nakayama, and K. Sonomoto. 2005. A novel type of immunity protein, NukH, for the lantibiotic nukacin ISK-1 produced by Staphylococcus warneri ISK-1. Biosci. Biotechnol. Biochem. 69:1403-1410.
3. Breukink, E., H. E. van Heusden, P. J. Vollmerhaus, E. Swiezewska, L. Brunner, S. Walker, A. J. Heck, and B. de Kruijff. 2003. Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J. Biol. Chem. 278:19898-19903.
4. Breukink, E., I. Wiedemann, C. van Kraaij, O. P. Kuipers, H.-G. Sahl, and B. de Kruijff. 1999. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286:2361-2364.
5. Brötz, H., G. Bierbaum, A. Markus, E. Molitor, and H.-G. Sahl. 1995. Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob. Agents Chemother. 39:714-719.
6. Brötz, H., M. Josten, I. Wiedemann, U. Schneider, F. Götz, G. Bierbaum, and H.-G. Sahl. 1998. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30:317-327.
7. Dufour, A., T. Hindre, D. Haras, and J.-P. Le Pennec. 2007. The biology of lantibiotics from the lacticin 481 group is coming of age. FEMS Microbiol. Rev. 31:134-167.
8. Hasper, H. E., N. E. Kramer, J. L. Smith, J. D. Hillman, C. Zachariah, O. P. Kuipers, B. de Kruijff, and E. Breukink. 2006. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313:1636-1637.
9. Hyde, A. J., J. Parisot, A. McNichol, and B. B. Bonev. 2006. Nisin-induced changes in Bacillus morphology suggest a paradigm of antibiotic action. Proc. Natl. Acad. Sci. USA 103:19896-19901.
10. Iida, H., L. Wang, K. Nishii, A. Ookuma, and Y. Shibata. 1996. Identification of rab12 as a secretory granule-associated small GTP-binding protein in atrial myocytes. Circ. Res. 78:343-347.
11. Jack, R., R. Benz, J. Tagg, and H.-G. Sahl. 1994. The mode of action of SA-FF22, a lantibiotic isolated from Streptococcus pyogenes strain FF22. Eur. J. Biochem. 219:699-705.
12. Jung, G. 1991. Lantibiotics: a survey, p. 1-34. In G. Jung and H.-G. Sahl (ed.), Nisin and novel lantibiotics. ESCOM, Leiden, The Netherlands.
13. Kimura, H., H. Matsusaki, T. Sashihara, K. Sonomoto, and A. Ishizaki. 1998. Purification and partial identification of bacteriocin ISK-1, a new lantibiotic produced by Pediococcus sp. ISK-1. Biosci. Biotechnol. Biochem. 62:2341-2345.
14. Wiedemann, I., E. Breukink, C. van Kraaij, O. P. Kuipers, G. Bierbaum, B. de Kruijff, and H.-G. Sahl. 2001. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 276:1772-1779.